top of page

Free Biopharma Daily Stock Updates - 07/12/21

$XBI $131.83 -1.5%


Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!


Pipeline Updates

$EQ +1.8% Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA source

$BSGM -2.6% BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care. source

$GLYC -3.6% GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination With Venetoclax and Azacitidine. source

$SMMT -1.2% Summit Therapeutics Presents Breakthrough Research Data from Ph II Studies, including Evidence Validating Microbiome Preservation, Potential Benefit for the Control of Antimicrobial Resistance, and a Novel Mechanism of Action, for its Investigational Drug Ridinilazole. source

$HALO +-0.0% Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse. source

$ARQT +2.0% Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis. source

$KALV -1.7% KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE. source

$PRTA -8.2% Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme. source

$TRVN -1.2% Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research. source

$PRVB +2.8% Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals. source

$BCRX -+0.0% BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline. source

$GLPG -0.30% Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis. source

$PHVS +-0.0% Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021. source

$CLDX +25.5% Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021. source

Financial Updates

$CLDX +25.5% Celldex Therapeutics Announces Proposed Public Offering of Common Stock source

$ISEE -6.2% IVERIC bio, Inc. Announces Proposed Offering of Common Stock source

$IDYA +6.5%IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares source


Posted by FS/JM

bottom of page